14th Annual “Discovery on Target” Conference - Prurisol
Boston, MA. September 19, 2016
“Prurisol: A New Small Molecule under investigation for the treatment of Psoriasis”
.
.
23rd Annual Newsmakers in the BioCentury Industry Conference
NY, NY. September 9, 2016
BIOCENTURY Sep 2016 Cellceutix_Corporate_Slide Deck
AUDIO -Newsmakers-In-Biotech-Conference-2016
.
.
“Dermatology Overview” - July 8, 2016
Please Click Here to View Slides
.
American Society for Microbiology - 2016
Boston, MA. June 16-20, 2016
Antifungal Potential of Peptide Mimetics in a Mouse Model of Invasive Candidiasis
American Society for Microbiology - 2016
Boston, MA. June 16-20, 2016
American Society for Microbiology - 2016
Boston, MA, June 16-20, 2016
Activity of Potent and Selective Host Defense Peptide Mimetics in Mouse Models of Oral Candidiasis
LD Micro 2016
Los Angeles, CA - Tuesday, June 7, 2016
Biotech Showcase 2016
San Francisco, CA– Monday, January 11, 2016
“Population Pharmacokinetics (PPK) of Brilacidin (BRI) in Healthy Subjects and Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI)” - Poster Walk
Joint 55th Interscience Conference on Antimicrobial Agents & Chemotherapy and 28thInternational Congress of Chemotherapy (ICAAC)
San Diego, CA - Friday, September 18, 2015
Although Brilacidin is from a brand new class of antibiotics, its distribution throughout the body, and its activity at the site of infection, have been described by standard mathematical models. This means that predictions can be made around the safety and efficacy of different dosing regimens based on demographic characteristics, such as body size, gender, and age. Because body weight did not seem to affect the level of brilacidin or its activity, we have an opportunity to give a fixed dose to every adult, or at least to the heavier ones (>90kg), rather than a different dose to each adult based on weight. This means that there is less of a risk of a “dosing error”—This is important in today’s health care system, as dosing errors can lead to either lower drug levels, which can decrease efficacy, or to higher drug levels, which can increase adverse reactions.
American Society of Clinical Oncology (ASCO)
Chicago, IL – Saturday, May 30, 2015
Understanding QIDP and Other 21st Century Incentives for Developing and Marketing Anti-Infective Medicines-Dr. Daniel Jorgensen
New York, New York– Monday, May 21, 2015
QIDP_21May2015 Power Point Presentation
CLICK HERE TO LISTEN TO LIVE WEBCAST
25th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID2015) Brilacidin- ABSSSI - Presentation
Copenhagen, Denmark – Monday, April 27, 2015
25th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID2015) Oral Mucositis-Poster
Copenhagen, Denmark – Sunday, April 26, 2015
ECCMID 2015 Oral Mucositis poster
Comparative Mechanistic Studies of Brilacidin, Daptomycin and the antimicrobial peptide LL16
Bruk Mensa, Gabriella L. Howell, Richard Scott, William F. DeGrado
AMERICAN SOCIETY FOR MICROBIOLOGY - JUNE 2014
Brilacidin PK-PD Data Presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2013
Posters
American Society of Clinical Oncology (ASCO)
Chicago, IL – Monday, June 3, 2013
American Association for Cancer Research
American Chemistry Society
